A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Latest Information Update: 15 May 2024
At a glance
- Drugs Efgartigimod alfa (Primary) ; Hyaluronidase; Prednisone
- Indications Bullous pemphigoid
- Focus Registrational; Therapeutic Use
- Acronyms BALLAD
- Sponsors argenx
- 09 May 2024 According to an Argenx media release, Update on this study is expected by end of 2024
- 16 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2023 According to an Argenx media release, the company is reviewing the BALLAD study in light of the ADDRESS results and the comparable biology between pemphigus and bullous pemphigoid, and has decided not to make a GO/NO GO decision at this time but rather wait for learnings from all currently enrolled patients and consider a new trial design for the path forward.